Genialis and Pancreatic Cancer Action Network (PanCAN) Partner to Progress KRAS Diagnostics

Genialis announced a new partnership with the Pancreatic Cancer Action Network to expand the validation of the Genialis™ krasID biomarker in the pancreatic cancer histology. Genialis krasID is a new Artificial Intelligence classifier that accurately predicts response and clinical benefit to KRAS inhibitors across preclinical, clinical, and real-world settings.